MTOR and cancer: To explore the possible mechanism by which downregulation of BICD1 contributed to a favorable outcome in LGG patients, we used the TCGA LGG cohort to analyze the correlation of BICD1 expression with a couple of representative markers involved in several important pathways associated with cancer progression, including the immune checkpoint (PD-1 and PD-L1), MET, STAT, and MTOR pathways.